We are live on ! Find out more

Incyte

INCY

Market cap $24.8B

122.19 USD

+0.72

0.59%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

122.31

+0.12

0.1%

1 day

0.59%

5 days

-1.55%

1 month

1.69%

3 months

19.82%

6 months

31.39%

Year to date

20.48%

1 year

46.97%

5 years

69.14%

10 years

52.64%

About: Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Employees: 2,844

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 54.2%

Neutral 45.8%

Negative 0%

Zacks Investment Research

INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?

Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.

INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?

Investors Business Daily

Profitable Biotech Incyte Forms Handle As Institutional Buyers Load Up On Stock

Incyte stock is trading just below a buy zone as Big Money gives it the stamp of approval.

Profitable Biotech Incyte Forms Handle As Institutional Buyers Load Up On Stock

Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Zacks Investment Research

Should First Trust Large Cap Growth AlphaDEX ETF (FTC) Be on Your Investing Radar?

Launched on May 8, 2007, the First Trust Large Cap Growth AlphaDEX ETF (FTC) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Growth segment of the US equity market.

Should First Trust Large Cap Growth AlphaDEX ETF (FTC) Be on Your Investing Radar?

Incyte Corporation: Why Jakafi Is No Longer The Real Story Here

Incyte Corporation is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. 2Q26 results showed 17% underlying net sales growth, broad-based portfolio expansion, and strong operating leverage despite one-time Opzelura CMS benefits. INCY's pipeline maturity and upcoming 2H26 clinical readouts across dermatology, hematology, and oncology are pivotal for validating its multi-engine growth thesis.

Incyte Corporation: Why Jakafi Is No Longer The Real Story Here

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present at Upcoming Investor Conferences.

Incyte to Present at Upcoming Investor Conferences

Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil

MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Project Orbis.

Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil

Zacks Investment Research

Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue?

7 Growth Stocks Holding Up in a Tough Market

Wolfe Research identified seven stocks combining strong earnings, rapid sales growth, and positive momentum in a tough market.

7 Growth Stocks Holding Up in a Tough Market

See News Rankings

Price charts implemented using Lightweight Charts™